Literature DB >> 23255438

Children's Oncology Group's 2013 blueprint for research: renal tumors.

Jeffrey S Dome1, Conrad V Fernandez, Elizabeth A Mullen, John A Kalapurakal, James I Geller, Vicki Huff, Eric J Gratias, David B Dix, Peter F Ehrlich, Geetika Khanna, Marcio H Malogolowkin, James R Anderson, Arlene Naranjo, Elizabeth J Perlman.   

Abstract

Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Year:  2012        PMID： 23255438      PMCID： PMC4127041          DOI： 10.1002/pbc.24419

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  58 in total

1.  Pregnancy outcome after treatment for Wilms tumor: a report from the national Wilms tumor long-term follow-up study.

Authors:  Daniel M Green; Jane M Lange; Eve M Peabody; Natalia N Grigorieva; Susan M Peterson; John A Kalapurakal; Norman E Breslow
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  The treatment of stages I-IV favorable histology Wilms' tumor.

Authors:  Daniel M Green
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

3.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.

Authors:  S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

4.  Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Authors:  Andrew J Wagner; John M Goldberg; Steven G Dubois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D Demetri
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

5.  Malignant rhabdoid tumours of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group.

Authors:  Marry M van den Heuvel-Eibrink; Harm van Tinteren; Harriet Rehorst; Aurore Coulombe; Catharine Patte; Beatriz de Camargo; Jan de Kraker; Ivo Leuschner; Rieneke Lugtenberg; Kathy Pritchard-Jones; Bengt Sandstedt; Filippo Spreafico; Norbert Graf; Gordan M Vujanic
Journal:  Pediatr Blood Cancer       Date:  2010-12-22       Impact factor: 3.167

6.  Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study.

Authors:  Jeffrey S Dome; Cecilia A Cotton; Elizabeth J Perlman; Norman E Breslow; John A Kalapurakal; Michael L Ritchey; Paul E Grundy; Marcio Malogolowkin; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Max J Coppes; Peter Coccia; Morris Kletzel; Robert M Weetman; Milton Donaldson; Roger M Macklis; Daniel M Green
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

7.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

Review 8.  The role of SMARCB1/INI1 in development of rhabdoid tumor.

Authors:  Charles W M Roberts; Jaclyn A Biegel
Journal:  Cancer Biol Ther       Date:  2009-03-29       Impact factor: 4.742

9.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

10.  Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.

Authors:  R Natrajan; S E Little; N Sodha; J S Reis-Filho; A Mackay; K Fenwick; A Ashworth; E J Perlman; J S Dome; P E Grundy; K Pritchard-Jones; C Jones
Journal:  J Pathol       Date:  2007-01       Impact factor: 7.996
View more
  57 in total

1.  Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.

Authors:  Alicia M Waters; Jerry E Stewart; Venkatram R Atigadda; Elizabeth Mroczek-Musulman; Donald D Muccio; Clinton J Grubbs; Elizabeth A Beierle
Journal:  Mol Cancer Ther       Date:  2016-02-12       Impact factor: 6.261

2.  High dose therapy for recurrent Wilms' tumor.

Authors:  Thomas W McLean
Journal:  Transl Pediatr       Date:  2014-01

3.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532.

Authors:  Conrad V Fernandez; Elizabeth J Perlman; Elizabeth A Mullen; Yueh-Yun Chi; Thomas E Hamilton; Kenneth W Gow; Fernando A Ferrer; Douglas C Barnhart; Peter F Ehrlich; Geetika Khanna; John A Kalapurakal; Tina Bocking; Vicky Huff; Jing Tian; James I Geller; Paul E Grundy; James R Anderson; Jeffrey S Dome; Robert C Shamberger
Journal:  Ann Surg       Date:  2017-04       Impact factor: 12.969

4.  Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor.

Authors:  Andrew J Murphy; Janene Pierce; Christian de Caestecker; Jaime Libes; David Neblett; Mark de Caestecker; Alan O Perantoni; Shunsuke Tanigawa; James R Anderson; Jeffrey S Dome; Amrita Das; Thomas J Carroll; Harold N Lovvorn
Journal:  Pediatr Blood Cancer       Date:  2013-09-20       Impact factor: 3.167

5.  Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.

Authors:  David B Dix; Conrad V Fernandez; Yueh-Yun Chi; Elizabeth A Mullen; James I Geller; Eric J Gratias; Geetika Khanna; John A Kalapurakal; Elizabeth J Perlman; Nita L Seibel; Peter F Ehrlich; Marcio Malogolowkin; James Anderson; Julie Gastier-Foster; Robert C Shamberger; Yeonil Kim; Paul E Grundy; Jeffrey S Dome
Journal:  J Clin Oncol       Date:  2019-08-26       Impact factor: 44.544

6.  Imaging Characteristics of Nephrogenic Rests Versus Small Wilms Tumors: A Report From the Children's Oncology Group Study AREN03B2.

Authors:  Jesse K Sandberg; Yueh-Yun Chi; Ethan A Smith; Sabah Servaes; Fredric A Hoffer; Elizabeth A Mullen; Elizabeth J Perlman; Brett Tornwall; Peter F Ehrlich; James I Geller; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome; Geetika Khanna
Journal:  AJR Am J Roentgenol       Date:  2020-03-11       Impact factor: 3.959

7.  Paediatrics: Integrating genomics to dig deeper into Wilms tumour biology.

Authors:  William Mifsud; Kathy Pritchard-Jones
Journal:  Nat Rev Urol       Date:  2017-10-25       Impact factor: 14.432

8.  Association of FOXM1 expression with tumor histology and prognosis in Wilms tumor: Potential for a new prognostic marker.

Authors:  Nadja Apelt; Jochen Hubertus; Doris Mayr; Norbert Graf; Rhoikos Furtwängler; Dietrich Von Schweinitz; Roland Kappler
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

9.  FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

10.  Race disparities in peptide profiles of North American and Kenyan Wilms tumor specimens.

Authors:  Jaime M Libes; Erin H Seeley; Ming Li; Jason R Axt; Janene Pierce; Hernan Correa; Mark Newton; Erik Hansen; Audra Judd; Hayes McDonald; Richard M Caprioli; Arlene Naranjo; Vicki Huff; James A O'Neill; Harold N Lovvorn
Journal:  J Am Coll Surg       Date:  2014-01-24       Impact factor: 6.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.